Breaking News

Sun Pharma, Merck enter into licensing agreement for psoriasis drug

Sun acquires rights to tildrakizumab for $80 million.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck and Sun Pharmaceutical have formed an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, (MK-3222), which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment. Under terms of the agreement, Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of $80 million. Merck will contin...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters